MarketInOut Stock Screener Log In | Sign Up
 

Harmony Biosciences Holdings Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 06/18/2026
Harmony Biosciences Holdings Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,955.04 mln
Float51.73 mln
Earnings Date08/11/2026

EPS

2.48
Solid

P / E

13.42
Fair value

Piotroski F-Score

4 / 9
Borderline

Beneish M-Score

-3.11
Reliable

1-Year Forecast

44.36
Strong upside

Relative Strength

69 / 100
Outperforming

Business Description

Harmony Biosciences Holdings is a pharmaceutical company based in Plymouth Meeting, Pennsylvania, focused on treating rare neurological conditions. Its flagship product, WAKIX, is an approved treatment for excessive daytime sleepiness in adults with narcolepsy, while its broader pipeline targets conditions such as Prader-Willi Syndrome, Fragile X Syndrome, Dravet Syndrome, and epilepsy. The company is advancing multiple drug candidates through clinical trials, including orexin receptor agonists and other compounds aimed at sleep disorders and seizure-related conditions. Founded in 2017, Harmony Biosciences serves patients across the United States who have limited treatment options for these complex and often underserved diseases.

Key Fundamentals

EPS2.48
P/E13.42
ROE17.72
RPS15.38
ROIC31.00
ROA12.31
Interest Cover13.49
EBITDA, mln237
EV / EBITDA5.36
EV / EBIT6.00
Revenue, mln899
EV / Revenue1.41

Financial Strength

Altman Z-Score4.94
Piotroski F-Score 4 / 9
Beneish M-Score-3.11
Price to Intrinsic Value0.66
Price to Lynch Fair Value0.51
Price to Graham Number1.15
1-Year Target Price44.36
Short Ratio8.00
Short % of Float13.73

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -5.45% 14 / 100   
1 Month 9.33% 79 / 100   
2 Months 19.76% 80 / 100   
6 Months -14.29% 26 / 100   
1 Year 2.49% 35 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us